Humalog Injection, Solution
NDC Package 50090-1663-0
Package Information
Humalog (insulin lispro) injection is insulin lispro is used with a proper diet and exercise program to control high blood sugar in people with diabetes. This formulation utilizes a injection, solution delivery system. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-1663 and is authorized under FDA application BLA020563.
Identification & Billing
- RxCUI: 1652639 - insulin lispro 100 UNT/ML in 3 ML Pen Injector
- RxCUI: 1652639 - 3 ML insulin lispro 100 UNT/ML Pen Injector
- RxCUI: 1652639 - insulin lispro 100 UNT/ML per 3 ML Pen Injector
- RxCUI: 1652640 - HumaLOG 100 UNT/ML in 3 ML Pen Injector
- RxCUI: 1652640 - 3 ML insulin lispro 100 UNT/ML Pen Injector [Humalog]
Clinical Specifications
- Intravenous - Administration within or into a vein or veins.
- Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Regulatory & Marketing
Hierarchy Structure
- 50090 - A-s Medication Solutions
- 50090-1663 - Humalog
- 50090-1663-0 - 5 SYRINGE in 1 CARTON / 3 mL in 1 SYRINGE
- 50090-1663 - Humalog
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50090-1663-0 identifies a specific commercial package of 5 syringe in 1 carton / 3 ml in 1 syringe of Humalog Kwikpen, a human prescription drug labeled by A-s Medication Solutions. This injection, solution is formulated for intravenous; subcutaneous use and contains insulin lispro as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by A-s Medication Solutions on September 06, 2007. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Insulin lispro is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin lispro is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin lispro starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product. Insulin lispro may also be used with other oral diabetes medications (such as sulfonylureas like glyburide or glipizide).
How is this A-s Medication Solutions product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090166300. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.
